Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity
Dina Medina‐Vera, Cristina Rosell‐Valle, Antonio J. López-Gambero, et al.
Biology (2020) Vol. 9, Iss. 11, pp. 377-377
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Behaviour Hallmarks in Alzheimer’s Disease 5xFAD Mouse Model
Mafalda Soares Pádua, José Luis Guil‐Guerrero, Paula A. Lopes
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6766-6766
Open Access | Times Cited: 15
Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer’s Disease
Julian M. Gaitán, Hyo Youl Moon, Matthew Stremlau, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 95
Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Giulia Abate, Daniela Uberti, Simone Tambaro
Biology (2021) Vol. 10, Iss. 6, pp. 542-542
Open Access | Times Cited: 71
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 11
A Negative Energy Balance Is Associated with Metabolic Dysfunctions in the Hypothalamus of a Humanized Preclinical Model of Alzheimer’s Disease, the 5XFAD Mouse
Antonio J. López-Gambero, Cristina Rosell‐Valle, Dina Medina‐Vera, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5365-5365
Open Access | Times Cited: 27
The Expression of the Endocannabinoid Receptors CB2 and GPR55 is Highly Increased during the Progression of Alzheimer’s Disease in AppNL-G-F Knock-In Mice
Dina Medina‐Vera, Hongjing Zhao, Erika Bereczki, et al.
Biology (2023) Vol. 12, Iss. 6, pp. 805-805
Open Access | Times Cited: 12
Transcending the amyloid-beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice
Dina Medina‐Vera, Emma Zambrana-Infantes, Antonio J. López-Gambero, et al.
Neurobiology of Disease (2023) Vol. 187, pp. 106295-106295
Open Access | Times Cited: 9
Neurolipid systems: A new target for the treatment of dementia
Gorka Pereira‐Castelo, Iker Bengoetxea de Tena, Jonatan Martínez‐Gardeazabal, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 135, Iss. 3, pp. 225-236
Open Access | Times Cited: 3
An enquiry to the role of CB1 receptors in neurodegeneration
Ignacio Fernández‐Moncada, Abel Eraso‐Pichot, Tommaso Dalla Tor, et al.
Neurobiology of Disease (2023) Vol. 184, pp. 106235-106235
Open Access | Times Cited: 7
Modulation of neuroinflammation and oxidative stress by targeting GPR55 – new approaches in the treatment of psychiatric disorders
Matthias Apweiler, Soraya Wilke Saliba, Lu Sun, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 12, pp. 3779-3788
Open Access | Times Cited: 2
Functional Selectivity of Coumarin Derivates Acting via GPR55 in Neuroinflammation
Matthias Apweiler, Jana Streyczek, Soraya Wilke Saliba, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 959-959
Open Access | Times Cited: 11
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Sonia Burgaz, Concepción García, Claudia Gonzalo‐Consuegra, et al.
Molecules (2021) Vol. 26, Iss. 24, pp. 7643-7643
Open Access | Times Cited: 15
Impact of the Cannabinoid System in Alzheimer's Disease
Shuangtao Li, Yuanbing Huang, Lijun Yu, et al.
Current Neuropharmacology (2022) Vol. 21, Iss. 3, pp. 715-726
Open Access | Times Cited: 10
Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion
Alberto Llorente‐Ovejero, Iker Bengoetxea de Tena, Jonatan Martínez‐Gardeazabal, et al.
ACS Pharmacology & Translational Science (2022) Vol. 5, Iss. 9, pp. 791-802
Open Access | Times Cited: 9
Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice
Laura Vidal-Palencia, Carla Ramon‐Duaso, Jose Antonio González-Parra, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling
Deepak Kumar, Ashish Sharma, Rajeev Taliyan, et al.
Ageing Research Reviews (2021) Vol. 73, pp. 101533-101533
Open Access | Times Cited: 9
Dietary administration of D-chiro-inositol attenuates sex-specific metabolic imbalances in the 5xFAD mouse model of Alzheimer’s disease
Antonio J. López-Gambero, Beatriz Pacheco-Sánchez, Cristina Rosell‐Valle, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112994-112994
Open Access | Times Cited: 6
Cannabidiol as a Treatment for Neurobiological, Behavioral, and Psychological Symptoms in Early-Stage Dementia: A Double-Blind, Placebo-Controlled Clinical Trial Protocol
Jessica G. Bartschi, Lisa‐Marie Greenwood, Amy Montgomery, et al.
Cannabis and Cannabinoid Research (2022)
Closed Access | Times Cited: 5
Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease
Ronnie D. Shade, Jennifer A. Ross, Elisabeth J. Van Bockstaele
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 5
WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2
Luiz Guilherme H. S. Aragão, Júlia Teixeira Oliveira, Jairo R. Temerozo, et al.
PeerJ (2021) Vol. 9, pp. e12262-e12262
Open Access | Times Cited: 7
Anti-Inflammatory Effects of GPR55 Agonists and Antagonists in LPS-Treated BV2 Microglial Cells
Lu Sun, Matthias Apweiler, Claus Normann, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 674-674
Open Access
Role of anandamide in Alzheimer's disease
Dina Medina‐Vera, Simone Tambaro
Elsevier eBooks (2024), pp. 419-443
Closed Access
Sex-Dependent Altered Expression of Cannabinoid Signaling in Hippocampal Astrocytes of the Triple Transgenic Mouse Model of Alzheimer’s Disease: Implications for Controlling Astroglial Activity
Beatriz Pacheco-Sánchez, Rubén Tovar, Meriem Ben Rabaa, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12598-12598
Open Access | Times Cited: 1
Analysis of Both Lipid Metabolism and Endocannabinoid Signaling Reveals a New Role for Hypothalamic Astrocytes in Maternal Caloric Restriction-Induced Perinatal Programming
Rubén Tovar, Antonio Vargas, Jesús Aranda, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6292-6292
Open Access | Times Cited: 2
Dementia: Alzheimer’s Disease
Kylie O’Brien, Philip Blair
Springer eBooks (2021), pp. 397-457
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top